retatrutide phase 2 trial type 2 diabetes results 2024 Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a 💉 A triple-action once-weekly injection

This is normal and expected with both tirzepatide and retatrutide

Rashmi Advani, director of bariatric endoscopy at Mount Sinais Center for Interventional Endoscopy and an assistant professor of medicine at the Icahn School of Medicine, said GLP-1 medications address one barrier to patients considering bariatric surgery or bariatric endoscopy access to health care facilities that provide this type of care

Overall, any potential benefits depend on individual clinical factors and should be discussed with a licensed healthcare provider

Weight loss drugs containing GLP-1 agonists have exploded in popularity in recent years, gaining the interest of consumers for usage far beyond the FDA-approved purpose to treat type 2 diabetes and obesity

Diet-induced obese (DIO) C57BL/6 J male mice were purchased from Jackson Laboratory (#380050, Bar Harbor, ME) at 16 weeks of age